Skip to main content
HUMA
NASDAQ Life Sciences

Humacyte 定价 2000 万美元注册直接发行，预示股权稀释

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$1.01
Mkt Cap
$204.576M
52W Low
$0.88
52W High
$3.36
Market data snapshot near publication time

summarizeSummary

Humacyte, Inc. 已宣布以 2000 万美元的价格定价注册直接发行普通股，向新机构投资者出售 25,000,000 股。这一融资事件利用了之前提交的 S-3 Shelf 登记，是重大的，因为发行金额几乎占公司当前市值的 10%，表明现有股东将面临重大稀释。这种发行通常会对股价施加下行压力。净收益将用于资助 Symvess® 在血管创伤中的商业化，支持计划在血液透析中提交生物制剂许可申请补充文件，推进产品线开发，并覆盖一般公司目的。投资者应监测预计在 2026 年 3 月 20 日左右完成的发行及其对股价的立即影响。

在该公告发布时，HUMA的交易价格为$1.01，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2亿。 52周交易区间为$0.88至$3.36。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed HUMA - Latest Insights

HUMA
Apr 28, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Humacyte Seeks Shareholder Approval to Increase Authorized Shares by 200 Million, Paving Way for Future Capital Raises
Sentiment: Neutral
View Wiseek Article
HUMA
Apr 24, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Humacyte Reclaims Global Commercial Rights for Symvess from Fresenius
Sentiment: Positive
View Wiseek Article
HUMA
Apr 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Israeli Ministry of Health Accepts Humacyte's Symvess MAA, Initiating 180-Day Review
Sentiment: Positive
View Wiseek Article
HUMA
Apr 17, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Humacyte Seeks Shareholder Approval to Increase Authorized Shares by 200 Million, Paving Way for Significant Future Dilution
Sentiment: Negative
View Wiseek Article
HUMA
Mar 27, 2026, 4:45 PM EDT
Filing Type: 10-K
Importance Score:
9
Humacyte Issues Going Concern Warning Amidst Low Revenue and Dilutive Financing
Sentiment: Negative
View Wiseek Article
HUMA
Mar 27, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Humacyte Reports Wider-Than-Expected Q4 Losses, Missing Operating and Net Income Estimates
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Humacyte Prices $20M Registered Direct Offering at Discount, Securing Capital for Operations
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 4:26 PM EDT
Filing Type: 424B3
Importance Score:
9
Humacyte Finalizes $20M Offering at Deep Discount, Discloses Substantial Doubt About Going Concern
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
$20M Registered Direct Offering Priced by Humacyte, Signaling Share Dilution
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 8:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Humacyte Halts $60M ATM Offering, Secures Saudi Arabia Deal, and Files for Israeli Approval
Sentiment: Positive
View Wiseek Article